Informações:
Falhas:
ID
34400
Descrição
Polymorphism Interaction to Predict Bevacizumab Efficacy; ODM derived from: https://clinicaltrials.gov/show/NCT01935102
Link
https://clinicaltrials.gov/show/NCT01935102
Palavras-chave
Versões (1)
- 17/01/2019 17/01/2019 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
17 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Metastatic Breast Cancer NCT01935102
Eligibility Metastatic Breast Cancer NCT01935102
- StudyEvent: Eligibility
Similar models
Eligibility Metastatic Breast Cancer NCT01935102
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
diagnosis histologically confirmed of metastatic breast cancer
boolean
ID.2
Item
age (from 18 to 90 years)
boolean
ID.3
Item
eastern cooperative oncology group (ecog) performance status (0 or 1-2)
boolean
ID.4
Item
hormonal-receptor status (positive or negative)
boolean
ID.5
Item
previous adjuvant chemotherapy (none, anthracycline or anthracycline plus taxane)
boolean
ID.6
Item
previous hormonal therapy (adjuvant or metastatic)disease-free interval from the first diagnosis of breast cancer (≤ or >12 months)
boolean
ID.7
Item
extent of disease (≤ or >3 sites)
boolean
ID.8
Item
location of disease (viscera or bone)
boolean
ID.9
Item
disease evaluation (measurable or non-measurable)and bevacizumab maintenance (yes or no).
boolean
ID.10
Item
patients with human epidermal growth factor receptor type 2 (her2)-positive
boolean